文献速递认知障碍与痴呆脑血管病

利用阿尔茨海默病病理、脑血管病和神经变性的基线指标预测老年人认知下降

Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration.
PubMed 文献 · Neurology · 2022-11-10

研究基于ADNI2/GO及ADNI3纵向数据,比较基线单时间点生物标志物(CSF淀粉样蛋白1-42、CSF ptau-181、白质高信号、脑微出血、全脑体积、海马体积)对认知正常者转为MCI(CNtoMCI,n=189)及MCI转为AD(MCItoAD,n=345)的预测能力。Cox回归显示,海马体积降低一致预测临床转化;CSF和脑体积标志物预测MCI转为AD,而白质高信号预测认知正常转为MCI。

要点

  • 海马体积降低是认知正常转为MCI和MCI转为AD的一致预测因素。
  • 白质高信号体积升高预测认知正常者转为MCI(完全调整模型HR 1.98)。
  • CSF ptau-181升高和CSF淀粉样蛋白1-42降低预测MCI转为AD。

核心结论

  • 海马体积降低一致预测临床转化为MCI和AD;CSF和脑体积标志物预测MCI转为AD,而白质高信号预测认知正常转为MCI。
  • CNtoMCI组中白质高信号的预测能力可能反映部分个体处于不同病理通路,如血管性认知障碍。

研究设计与样本

  • 研究使用AD神经影像倡议2(ADNI2)/GO的标准化基线生物标志物数据及纵向诊断数据(包括ADNI3)。
  • 采用Cox回归模型评估基线生物标志物与临床诊断变化时间的关系,模型分别对单个标志物及多变量联合进行拟合,并分别在CNtoMCI组(n=189)和MCItoAD组(n=345)中分析。

主要发现

  • CNtoMCI组(n=189):较高的白质高信号体积(单变量模型:HR 1.79,p=0.002;完全调整模型:HR 1.98,p=0.003)和较低的海马体积(单变量:HR 0.54,p=0.001;完全调整:HR 0.40,p<0.001)与转化为MCI独立相关。
  • MCItoAD组(n=345):较低的海马体积(单变量模型:HR 0.45,p<0.001;完全调整模型:HR 0.55,p<0.001)、较低的全脑体积(单变量:HR 0.31,p<0.001;完全调整:HR 0.48,p=0.02)、升高的CSF ptau(单变量:HR 1.88,p<0.001;完全调整:HR 1.61,p<0.001)和降低的CSF淀粉样蛋白(单变量:HR 0.37,p<0.001;完全调整:HR 0.62,p=0.008)与转化为AD独立相关。

关键数值与推荐

  • CNtoMCI组白质高信号体积单变量模型HR 1.79(p=0.002),完全调整模型HR 1.98(p=0.003)。
  • CNtoMCI组海马体积单变量模型HR 0.54(p=0.001),完全调整模型HR 0.40(p<0.001)。
  • MCItoAD组海马体积单变量模型HR 0.45(p<0.001),完全调整模型HR 0.55(p<0.001)。
  • MCItoAD组全脑体积单变量模型HR 0.31(p<0.001),完全调整模型HR 0.48(p=0.02)。
  • MCItoAD组CSF ptau单变量模型HR 1.88(p<0.001),完全调整模型HR 1.61(p<0.001);CSF淀粉样蛋白单变量模型HR 0.37(p<0.001),完全调整模型HR 0.62(p=0.008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Dementia is a growing socioeconomic challenge that requires early intervention. Identifying biomarkers that reliably predict clinical progression early in the disease process would better aid selection of individuals for future trial participation. Here, we compared the ability of baseline, single time-point biomarkers (CSF amyloid 1-42, CSF ptau-181, white matter hyperintensities (WMH), cerebral microbleeds, whole-brain volume, and hippocampal volume) to predict decline in cognitively normal individuals who later converted to mild cognitive impairment (MCI) (CNtoMCI) and those with MCI who later converted to an Alzheimer disease (AD) diagnosis (MCItoAD). METHODS: Standardized baseline biomarker data from AD Neuroimaging Initiative 2 (ADNI2)/GO and longitudinal diagnostic data (including ADNI3) were used. Cox regression models assessed biomarkers in relation to time to change in clinical diagnosis using all follow-up time points available. Models were fit for biomarkers univariately and together in a multivariable model. Hazard ratios (HRs) were compared to evaluate biomarkers. Analyses were performed separately in CNtoMCI and MCItoAD groups. RESULTS: For CNtoMCI (n = 189), there was strong evidence that higher WMH volume (individual model: HR 1.79, p = 0.002; fully adjusted model: HR 1.98, p = 0.003) and lower hippocampal volume (individual: HR 0.54, p = 0.001; fully adjusted: HR 0.40, p < 0.001) were associated with conversion to MCI individually and independently. For MCItoAD (n = 345), lower hippocampal (individual model: HR 0.45, p < 0.001; fully adjusted model: HR 0.55, p < 0.001) and whole-brain volume (individual: HR 0.31, p < 0.001; fully adjusted: HR 0.48, p = 0.02), increased CSF ptau (individual: HR 1.88, p < 0.001; fully adjusted: HR 1.61, p < 0.001), and lower CSF amyloid (individual: HR 0.37, p < 0.001; fully adjusted: HR 0.62, p = 0.008) were most strongly associated with conversion to AD individually and independently. DISCUSSION: Lower hippocampal volume was a consistent predictor of clinical conversion to MCI and AD. CSF and brain volume biomarkers were predictive of conversion to AD from MCI, whereas WMH were predictive of conversion to MCI from cognitively normal. The predictive ability of WMH in the CNtoMCI group may be interpreted as some being on a different pathologic pathway, such as vascular cognitive impairment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Prosser L, Macdougall A, Sudre CH, et al. Predicting Cognitive Decline in Older Adults Using Baseline Metrics of AD Pathologies, Cerebrovascular Disease, and Neurodegeneration. Neurology. 2022. PMID: 36357185. doi:10.1212/WNL.0000000000201572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。